• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma.

作者信息

Dytfeld Dominik, Jasielec Jagoda, Griffith Kent A, Lebovic Daniel, Vesole David H, Jagannath Sundar, Al-Zoubi Ammar, Anderson Tara, Detweiler-Short Kristen, Stockerl-Goldstein Keith, Ahmed Asra, Jobkar Terri, Durecki Diane E, McDonnell Kathryn, Mietzel Melissa, Couriel Daniel, Kaminski Mark, Vij Ravi, Jakubowiak Andrzej J

机构信息

University of Chicago, Chicago, IL, USA University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA Karol Marcinkowski University of Medical Sciences, Poznan, Poland.

University of Chicago, Chicago, IL, USA.

出版信息

Haematologica. 2014 Sep;99(9):e162-4. doi: 10.3324/haematol.2014.110395. Epub 2014 Jun 27.

DOI:10.3324/haematol.2014.110395
PMID:24972772
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4562550/
Abstract
摘要

相似文献

1
Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma.卡非佐米、来那度胺与低剂量地塞米松用于老年新诊断多发性骨髓瘤患者的治疗
Haematologica. 2014 Sep;99(9):e162-4. doi: 10.3324/haematol.2014.110395. Epub 2014 Jun 27.
2
Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan.卡非佐米、来那度胺和地塞米松用于多次预处理的多发性骨髓瘤患者：日本的一项1期研究。
Cancer Sci. 2017 Mar;108(3):461-468. doi: 10.1111/cas.13166.
3
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.来那度胺扩展疗程的卡非佐米-来那度胺-地塞米松治疗冒烟型或新诊断多发性骨髓瘤患者。
JAMA Oncol. 2015 Sep;1(6):746-54. doi: 10.1001/jamaoncol.2015.2010.
4
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.硼替佐米联合来那度胺和地塞米松与单纯来那度胺和地塞米松治疗新诊断的无立即自体干细胞移植意向的骨髓瘤患者（SWOG S0777）：一项随机、开放标签的3期试验
Lancet. 2017 Feb 4;389(10068):519-527. doi: 10.1016/S0140-6736(16)31594-X. Epub 2016 Dec 23.
5
Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.卡非佐米、来那度胺和低剂量地塞米松联合治疗复发或进展性多发性骨髓瘤的 Ib 期剂量递增研究（PX-171-006）。
Clin Cancer Res. 2013 Apr 15;19(8):2248-56. doi: 10.1158/1078-0432.CCR-12-3352. Epub 2013 Feb 27.
6
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.卡非佐米、来那度胺和地塞米松治疗复发多发性骨髓瘤。
N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6.
7
Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.硼替佐米联合来那度胺及地塞米松每周给药方案用于首次复发或原发性难治性骨髓瘤的I/II期试验
Haematologica. 2016 Apr;101(4):e149-52. doi: 10.3324/haematol.2015.132431. Epub 2015 Dec 11.
8
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.每周一次与每周两次卡非佐米给药治疗复发和难治性多发性骨髓瘤患者（A.R.R.O.W.）：一项随机、3 期研究的中期分析结果。
Lancet Oncol. 2018 Jul;19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1. Epub 2018 Jun 1.
9
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.在FIRST试验中，肾功能损害对来那度胺和地塞米松治疗结局的影响，这是一项针对不符合移植条件的多发性骨髓瘤患者的随机、开放标签3期试验。
Haematologica. 2016 Mar;101(3):363-70. doi: 10.3324/haematol.2015.133629. Epub 2015 Dec 11.
10
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.卡非佐米、来那度胺和低剂量地塞米松治疗复发或进展性多发性骨髓瘤的 2 期剂量扩展研究（PX-171-006）。
Blood. 2013 Oct 31;122(18):3122-8. doi: 10.1182/blood-2013-07-511170. Epub 2013 Sep 6.

引用本文的文献

1
Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies.多发性骨髓瘤一线治疗的演变：含卡非佐米和抗CD38单克隆抗体的四联方案的临床研究
Ann Hematol. 2025 Mar;104(3):1329-1351. doi: 10.1007/s00277-024-06143-7. Epub 2025 Jan 8.
2
Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myeloma.卡非佐米、来那度胺和地塞米松治疗既往大量治疗的多发性骨髓瘤的 I 期研究的最终结果。
Int J Hematol. 2020 Jan;111(1):57-64. doi: 10.1007/s12185-019-02754-3. Epub 2019 Oct 29.
3
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma.卡非佐米联合免疫调节剂治疗新诊断多发性骨髓瘤。
Leukemia. 2019 Sep;33(9):2127-2143. doi: 10.1038/s41375-019-0517-6. Epub 2019 Jul 24.
4
Approach to the Older Adult With Multiple Myeloma.老年多发性骨髓瘤的治疗方法
Am Soc Clin Oncol Educ Book. 2019 Jan;39:500-518. doi: 10.1200/EDBK_239067. Epub 2019 May 17.
5
Once-weekly twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies.每周一次、每周两次卡非佐米治疗新诊断多发性骨髓瘤患者：两项 I/II 期研究的汇总分析。
Haematologica. 2019 Aug;104(8):1640-1647. doi: 10.3324/haematol.2018.208272. Epub 2019 Feb 7.
6
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).现代骨髓瘤治疗中的心血管不良事件 - 发生率和风险。来自欧洲骨髓瘤网络（EMN）和意大利动脉高血压学会（SIIA）的综述。
Haematologica. 2018 Sep;103(9):1422-1432. doi: 10.3324/haematol.2018.191288. Epub 2018 Jul 26.
7
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.来那度胺-地塞米松联合两周一次伊沙佐米治疗新诊断多发性骨髓瘤患者。
Br J Haematol. 2018 Jul;182(2):231-244. doi: 10.1111/bjh.15394. Epub 2018 Jun 25.
8
Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.基于卡非佐米的方案治疗多发性骨髓瘤的疗效和毒性特征：系统评价。
Crit Rev Oncol Hematol. 2018 May;125:1-11. doi: 10.1016/j.critrevonc.2018.02.008. Epub 2018 Mar 2.
9
Management of multiple myeloma in the newly diagnosed patient.新诊断多发性骨髓瘤患者的管理。
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):498-507. doi: 10.1182/asheducation-2017.1.498.
10
Managing multiple myeloma in elderly patients.老年多发性骨髓瘤的管理
Leuk Lymphoma. 2018 Jun;59(6):1300-1311. doi: 10.1080/10428194.2017.1365859. Epub 2017 Aug 28.

本文引用的文献

1
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.硼替佐米-马法兰-泼尼松-沙利度胺序贯治疗随后硼替佐米-沙利度胺维持治疗与硼替佐米-马法兰-泼尼松方案比较用于初治多发性骨髓瘤：更新随访结果和改善生存。
J Clin Oncol. 2014 Mar 1;32(7):634-40. doi: 10.1200/JCO.2013.52.0023. Epub 2014 Jan 21.
2
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.单药卡非佐米的综合安全性概况：来自 4 项 II 期临床研究中纳入的 526 例患者的经验。
Haematologica. 2013 Nov;98(11):1753-61. doi: 10.3324/haematol.2013.089334. Epub 2013 Aug 9.
3
Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.改善细胞遗传学高危多发性骨髓瘤治疗中的总体生存并克服不良预后。
Blood. 2013 Feb 7;121(6):884-92. doi: 10.1182/blood-2012-05-432203. Epub 2012 Nov 19.
4
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.一项单药卡非佐米（PX-171-003-A1）治疗复发/难治性多发性骨髓瘤患者的 II 期研究。
Blood. 2012 Oct 4;120(14):2817-25. doi: 10.1182/blood-2012-05-425934. Epub 2012 Jul 25.
5
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.硼替佐米诱导和维持治疗新诊断多发性骨髓瘤患者：随机 III 期 HOVON-65/GMMG-HD4 试验结果。
J Clin Oncol. 2012 Aug 20;30(24):2946-55. doi: 10.1200/JCO.2011.39.6820. Epub 2012 Jul 16.
6
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.一项卡非佐米联合来那度胺和低剂量地塞米松作为多发性骨髓瘤一线治疗的 1/2 期研究。
Blood. 2012 Aug 30;120(9):1801-9. doi: 10.1182/blood-2012-04-422683. Epub 2012 Jun 4.
7
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.来那度胺持续治疗新诊断的多发性骨髓瘤。
N Engl J Med. 2012 May 10;366(19):1759-69. doi: 10.1056/NEJMoa1112704.
8
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.多发性骨髓瘤风险分层的共识建议：国际骨髓瘤工作组共识小组报告 2.
Blood. 2011 May 5;117(18):4696-700. doi: 10.1182/blood-2010-10-300970. Epub 2011 Feb 3.
9
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients.新型药物治疗老年骨髓瘤患者的完全缓解与长期无进展生存和总生存相关：对 1175 例患者的分析。
Blood. 2011 Mar 17;117(11):3025-31. doi: 10.1182/blood-2010-09-307645. Epub 2011 Jan 12.
10
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.硼替佐米、马法兰和泼尼松与硼替佐米、沙利度胺和泼尼松作为诱导治疗，随后用硼替佐米和沙利度胺维持治疗与硼替佐米和泼尼松治疗未经治疗的老年多发性骨髓瘤患者：一项随机试验。
Lancet Oncol. 2010 Oct;11(10):934-41. doi: 10.1016/S1470-2045(10)70187-X. Epub 2010 Aug 23.